Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is used in the management of hypertension, targeting several physiological pathways that regulate blood pressure.

• Hypertension: improves blood pressure control when monotherapy is insufficient.
• Hypertensive heart disease: reduces cardiac workload and risk of progression.
• Chronic kidney disease with hypertension: helps slow renal function decline associated with high blood pressure.

• The combination product contains three agents that act synergistically: olmesartan medoxil blocks the angiotensin II type 1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide increases urinary sodium and water excretion, lowering plasma volume. Together they lower systemic vascular resistance and cardiac output, resulting in reduced arterial pressure.

Adverse reactions may vary depending on the individual component and patient characteristics.

Common Side Effects

• Dizziness or light‑headed headache.
• Peripheral edema, especially related to amlodipine.
• Cough or mild upper‑respiratory irritation.
• Increased urination or electrolyte changes.
• Fatigue or general weakness.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Acute kidney injury or significant rise in serum creatinine.
• Hyperkalemia or severe electrolyte imbalance.
• Angio‑edema involving the face, lips or airway.
• Hepatotoxicity presenting as jaundice or abnormal liver enzymes.
• Blood dyscrasias such as agranulocytosis or thrombocytopenia.

When prescribing this combination, clinicians should consider patient history, comorbidities, and concurrent therapies.

• Renal impairment: adjust monitoring and avoid excessive diuretic use.
• Hepatic dysfunction: use with caution; monitor liver enzymes.
• Electrolyte disturbances: check serum potassium and sodium regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Elderly patients: start at lower doses and monitor for orthostatic hypotension.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of renal failure and hyperkalaemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function.
• Lithium: increased risk of lithium toxicity.
• Antidiabetic agents: may enhance hypoglycaemic effect.
• Antacids containing aluminium or magnesium: may affect absorption of olmesartan.
• Alcohol: additive vasodilatory effect leading to dizziness.